F2 and thrombophilia: The 67 patients with VTE on TT also were more likely than the 76 VTE no-TT controls to have the lupus anticoagulant, 9/64 (14%) versus 2/76, 3%, P = .023.4 When screening men4 for thrombophilia before starting TT, we suggest that minimal tests include the factor V Leiden mutation and the lupus anticoagulant, while more extensive tests would also include PCR for the G20210A prothrombin gene mutation, factors VIII and XI, and homocysteine.